OLEMA PHARMACEUTICALS, INC. Proceeds from Lines of Credit
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Proceeds from Lines of Credit of $3.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. proceeds from lines of credit for the quarter ending 2025-12-31 was $0.00.
- OLEMA PHARMACEUTICALS, INC. proceeds from lines of credit for the quarter ending 2025-09-30 was $0.00.
- OLEMA PHARMACEUTICALS, INC. proceeds from lines of credit for fiscal 2025 was $3.00M.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $3.00M 10-K · filed 2026-03-16 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $3.00M 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | $3.00M 10-Q · filed 2026-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |